Chiesi to acquire KalVista for $1.9 billion, adding oral hereditary angioedema drug Ekterly to its rare-disease portfolio

Chiesi Group announced it will purchase KalVista Pharmaceuticals for $1.9 billion, gaining ownership of Ekterly, an oral on‑demand treatment for hereditary angioedema (HAE).

Ekterly received FDA approval in July after a brief delay and generated nearly $50 million in sales last year, marking the first oral therapy for the rare swelling disorder.

The acquisition, the fifth biotech deal for Chiesi this week, is intended to bolster its rare‑disease business and expand its commercial presence in the United States.

Chiesi said the purchase will help it meet its 2030 revenue goal of €6 billion (about $7 billion) and reflects growing industry interest in oral treatments for HAE.